BioSpace News Archive

Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Peter K. Maag, Ph.D., as the company’s chief executive officer (CEO).

Alpha Teknova, Inc. announced the creation of an Early Access Program for two new products currently in development to streamline downstream gene therapy process development, including an Anion Exchange Buffer Screening Kit and a Functional Reporter Assay.

Tyra Biosciences, Inc. today announced that the Company will present preclinical data on TYRA-200 during a poster session at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 26-28, 2022, in Barcelona, Spain.

DarioHealth Corp. announced that a mid-sized Midwestern city selected Dario to provide its full suite of digital therapeutics solutions to several thousand city employees beginning in the first quarter of 2023.

INOVIO today announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.

Aytu BioPharma, Inc. today announced a shift of the Company’s strategy aimed at accelerating the growth of its commercial business and achieving profitability.

Some of the most influential international medical experts, researchers and scientific minds participated in the fifth Bioelectronic Medicine Summit, “Bioelectronic Medicine: Today’s Tools, Tomorrow’s Therapies,” hosted by The Feinstein Institutes for Medical Research.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes.